Search Result

Pathways Recommended:	TGF-beta/Smad

Results for "

TGF-�� Receptor

" in MCE Product Catalog:

By Targets:	TGF-beta/Smad (6) TGF-β Receptor (23) Apelin Receptor (APJ) (1) Apoptosis (5) Autophagy (1) Calcium Channel (2) DNA/RNA Synthesis (2) EGFR (1) Estrogen Receptor/ERR (4) FGFR (1) Parasite (2) PD-1/PD-L1 (1) PDGFR (1) PI3K (3) Prostaglandin Receptor (1) Protease Activated Receptor (PAR) (1) Sodium Channel (2) Src (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (4) Endocrinology (5) Infection (2) Inflammation/Immunology (10) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: TGF-β Receptor TGF-beta/Smad

Cat. No.	Product Name	Target	Research Areas

HY-114192

TGFβRI-IN-1	TGF-β Receptor	Cancer
TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC₅₀ values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .

HY-13226

Galunisertib
LY2157299
TGF-β Receptor Cancer

Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

Galunisertib LY2157299	TGF-β Receptor	Cancer
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

HY-146780

TGFβRI-IN-4	TGF-β Receptor	Cancer
TGFβRI-IN-4 is a highly potent and orally active TGFβ receptor type I (TGFβRI) inhibitor, with IC₅₀s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model.

HY-P2294

pm26TGF-β1 peptide	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide shows high affinity for the **TGF-β1 receptor**. pm26TGF-β1 peptide displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction.

HY-12704

ITD-1
TGF-β Receptor Cardiovascular Disease

ITD-1 is the first selective TGFβ receptor inhibitor with an IC₅₀ of 460 nM.

ITD-1	TGF-β Receptor	Cardiovascular Disease
ITD-1 is the first selective **TGFβ receptor inhibitor with an IC₅₀** of 460 nM.

HY-P2294A

pm26TGF-β1 peptide TFA	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the **TGF-β1 receptor**. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction.

HY-12075

LY2109761
TGF-β Receptor Autophagy Cancer

LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with K_is of 38 nM and 300 nM, respectively.

LY2109761	TGF-β Receptor Autophagy	Cancer
LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with K_is of 38 nM and 300 nM, respectively.

HY-10326

GW788388	TGF-β Receptor	Cancer
GW788388 is a potent and selective inhibitor of ALK5 with IC₅₀ of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.

HY-13783

BIBF0775
TGF-β Receptor Cancer

BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC₅₀ of 34 nM.

BIBF0775	TGF-β Receptor	Cancer
BIBF0775 is a potent and selective *transforming growth factor β (TGFβ) type I receptor* (Alk5) inhibitor with an IC₅₀** of 34 nM.

HY-P3970

KRFK	TGF-β Receptor	Inflammation/Immunology
KRFK, a peptide derived from TSP-1, can activate *TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors* such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach.

HY-78349

A 77-01
TGF-β Receptor Cancer

A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC₅₀ of 25 nM.

A 77-01	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC₅₀ of 25 nM.

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment.

HY-100448A

Butaprost	Prostaglandin Receptor TGF-beta/Smad	Endocrinology
Butaprost is a selective *prostaglandin E receptor* (EP2) agonist with an EC₅₀ of 33 nM and a K_i** of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost attenuates fibrosis by hampering *TGF-β/Smad2* signalling.

HY-10432

A 83-01	TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.

HY-10431

SB-431542	TGF-β Receptor Apoptosis	Cancer
SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.

HY-13521

SB-505124	TGF-β Receptor	Cancer
SB-505124 is a selective inhibitor of TGF-β **Receptor type I receptors (ALK4, ALK5, ALK7), with IC₅₀**s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.

HY-13521A

SB-505124 hydrochloride	TGF-β Receptor	Cancer
SB-505124 hydrochloride is a selective inhibitor of TGF-β **Receptor type I receptor (ALK4, ALK5, ALK7), with IC₅₀**s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.

HY-N2589

Isosaponarin	TGF-β Receptor	Others
Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin increases collagen synthesis, caused by up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production.

HY-142949

ALK5-IN-7	TGF-β Receptor	Cancer Inflammation/Immunology
ALK5-IN-7 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-7 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 4).

HY-142950

ALK5-IN-6	TGF-β Receptor	Cancer Inflammation/Immunology
ALK5-IN-6 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-6 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 1).

HY-10432A

A 83-01 sodium	TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.

HY-103021

LY3200882	TGF-β Receptor	Cancer Inflammation/Immunology
LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC₅₀ of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent.

HY-P0118B

Disitertide diammonium P144 diammonium	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer.

HY-P0118

Disitertide P144	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer.

HY-P0118A

Disitertide TFA P144 TFA	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer.

HY-10431G

SB-431542	TGF-β Receptor	Cancer Neurological Disease
SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling.

HY-135581

Raloxifene 6-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression.

HY-135582

Raloxifene 4'-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression.

HY-13012

RepSox E-616452; SJN 2511	TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.

HY-100434

PD-161570	FGFR PDGFR EGFR Src TGF-β Receptor	Cancer Cardiovascular Disease
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC₅₀ of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC₅₀ values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC₅₀s of 450 nM and 622 nM, respectively. PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor.

HY-124748A

ENMD-1068 hydrochloride	Protease Activated Receptor (PAR) Apoptosis	Inflammation/Immunology
ENMD-1068 hydrochloride is a selective *protease-activated receptor* 2 (PAR2) antagonist. ENMD-1068 hydrochloride reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 hydrochloride also inhibits the proliferation of endometrial cells and induces apoptosis** of epithelial cells in the lesion. ENMD-1068 hydrochloride can be used in the study of endometriosis and liver fibrosis.

HY-110246

Quin C1	Others	Inflammation/Immunology
Quin C1 is a highly specific and potent agonist for formyl peptide receptor 2 (FPR2/ALX). Quin-C1 significantly reduces the neutrophil and lymphocyte counts in BALF, diminishes expression of TNF-α, IL-1β, KC, and TGF-β1, and decreases collagen deposition in lung tissue. Quin C1 has the potential for the research of lung injury.

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium	Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium	Estrogen Receptor/ERR	Endocrinology
Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. [1][2]. Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[3].

HY-N1584

Halofuginone RU-19110	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Cancer Infection Inflammation/Immunology Cardiovascular Disease
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca²⁺ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.

HY-N1584A

Halofuginone hydrobromide RU-19110 hydrobromide	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Cancer Infection Inflammation/Immunology Cardiovascular Disease
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca²⁺ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.

HY-P2196A

ELA-32(human) TFA	Apelin Receptor (APJ)
ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC₅₀=0.27 nM; K_d=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library	178 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc. MCE designs a unique collection of 178 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

TGF-beta/Smad Compound Library

178 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 178 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

HY-L074

Anti-Breast Cancer Compound Library	1687 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 1687 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

1687 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 1687 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Target	Research Area

HY-P2294

pm26TGF-β1 peptide	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide shows high affinity for the **TGF-β1 receptor**. pm26TGF-β1 peptide displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction.

HY-P2294A

pm26TGF-β1 peptide TFA	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the **TGF-β1 receptor**. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction.

HY-P3970

KRFK	TGF-β Receptor	Inflammation/Immunology
KRFK, a peptide derived from TSP-1, can activate *TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors* such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach.

HY-P0118B

Disitertide diammonium P144 diammonium	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer.

HY-P0118

Disitertide P144	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer.

HY-P0118A

Disitertide TFA P144 TFA	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer.

HY-P2196A

ELA-32(human) TFA	Apelin Receptor (APJ)
ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC₅₀=0.27 nM; K_d=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.

Cat. No.	Product Name	Target	Research Area

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment.

Cat. No.	Product Name	Target	Category

HY-N2589

Isosaponarin	TGF-β Receptor	Flavonoids Flavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Other Diseases Source classification Plants Caryophyllaceae Vaccaria segetalis (Neck.) Garcke
Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin increases collagen synthesis, caused by up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production.

HY-N1584

Halofuginone RU-19110	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Alkaloids Piperidine Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Infection Inflammation/Immunology Source classification Plants Saxifragaceae Dichroa febrifuga Lour
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca²⁺ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.

HY-N1584A

Halofuginone hydrobromide RU-19110 hydrobromide	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Alkaloids Piperidine Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Infection Inflammation/Immunology Source classification Plants Saxifragaceae Dichroa febrifuga Lour
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca²⁺ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.

Species:	Human (10) Rhesus Macaque (1) Mouse (5) Rat (1)
Tag:	His (10) Myc (1) GST (1) Fc (9)
Source:	HEK293 (14) Sf9 insect cells (1) Sf9 insect cells (2)

Cat. No.	Product Name	Species	Source

HY-P7426

TGFBR2/TGF-beta RII Protein, Human (HEK293, Fc) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Human	HEK293
TGF-beta receptor 2 Protein, Human (HEK293, Fc), a fragment of transforming growth factor-beta receptor type 2 (TβRII), consists of amino acid of Thr23-Asp159 with an Fc tag at the C-terminus.

HY-P7427

TGFBR2/TGF-beta RII Protein, Mouse (HEK293, Fc) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Mouse	HEK293
TGFBR2/TGF-beta RII Protein, Mouse (HEK293, Fc), a fragment of transforming growth factor-beta receptor type 2 (TβRII), consists of amino acid of Ile24-Asp159 with a 6His tag at the C-terminus.

HY-P7428

TGFBR2/TGF-beta RII Protein, Mouse (HEK293, His) TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II	Mouse	HEK293
TGFBR2/TGF-beta RII Protein, Mouse (HEK293, His), His consists of N-terminal ectodomain and C-terminal protein kinase domain with his tag. TGF-beta receptor type-2 is the ligand-binding receptor for all members of the TGF-β family.

HY-P73428

TGFBR2/TGF-beta RII Protein, Human (sf9, His)
TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II
Human Sf9 insect cells
HY-P73430

TGFBR2/TGF-beta RII Protein, Rat (HEK293, Fc)
TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II
Rat HEK293
HY-P73429

TGFBR2/TGF-beta RII Protein, Human (HEK293, His-Fc)
TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II
Human HEK293
HY-P77229

TGFBR2/TGF-beta RII Protein, Rhesus Macaque (HEK293, Fc)
TGFR-2; TGF-beta type II Receptor; TGF-beta Receptor type 2; TbetaR-II
Rhesus Macaque HEK293
HY-P74521

TGFBR3/TGF-beta RIII Protein, Human (sf9, His)
TGFBR3; TGF-bRIII; TGFR-3; Transforming growth factor beta Receptor III; Betaglycan
Human Sf9 insect cells
HY-P72452

TGFBR3/TGF-beta RIII Protein, Mouse (763a.a, HEK293, His)
TGFBR3; TGF-bRIII; TGFR-3; Transforming growth factor beta Receptor III
Mouse HEK293
HY-P72454

TGFBR1/ALK-5 Protein, Mouse (HEK293, Fc)
TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5
Mouse HEK293
HY-P74522

TGFBR1/ALK-5 Protein, Human (sf9, His-GST)
TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5
Human Sf9 insect cells
HY-P74523

TGFBR1/ALK-5 Protein, Human (HEK293, His-Fc)
TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5
Human HEK293
HY-P72453

TGFBR1/ALK-5 Protein, Human (92a.a, HEK293, Fc)
TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5
Human HEK293
HY-P74524

TGFBR1/ALK-5 Protein, Human (126a.a, HEK293, Fc)
TGF-beta Receptor type-1; ALK-5; SKR4; TbetaR-I; AAT5
Human HEK293

HY-P70192

GFRA2/GDNFR-alpha-2 Protein, Human (HEK293, His) rHuGDNF family Receptor alpha-2/GFRA2, His ; GDNF Family Receptor Alpha-2; GDNF Receptor Alpha-2; GDNFR-Alpha-2; GFR-Alpha-2; GDNF Receptor Beta; GDNFR-Beta; Neurturin Receptor Alpha; NRTNR-Alpha; NTNR-Alpha; RET Ligand 2; TGF-Beta-Related Neurotrophic Factor Receptor 2; GFRA2; GDNFRB; RETL2; TRNR2	Human	HEK293

HY-P70384

GFRA1/GDNFR-alpha-1 Protein, Human (410a.a, HEK293, His) rHuGDNF family Receptor alpha-1/GFRA1, His; GFRα1; GDNF Family Receptor Alpha-1; GDNF Receptor Alpha-1; GDNFR-Alpha-1; GFR-Alpha-1; RET Ligand 1; TGF-Beta-Related Neurotrophic Factor Receptor 1; GFRA1; GDNFRA; RETL1; TRNR1	Human	HEK293

HY-P700449

GFRA1/GDNFR-alpha-1 Protein, Mouse (HEK293, N-His, C-Myc) rHuGDNF family Receptor alpha-1/GFRA1, His; GFRα1; GDNF Family Receptor Alpha-1; GDNF Receptor Alpha-1; GDNFR-Alpha-1; GFR-Alpha-1; RET Ligand 1; TGF-Beta-Related Neurotrophic Factor Receptor 1; GFRA1; GDNFRA; RETL1; TRNR1	Mouse	HEK293

Cat. No.	Product Name

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium

Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium

Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC50 of 370 μM. [1][2]. Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[3].

TGF-�� Receptor

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products